Manhattan West Asset Management’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Manhattan West Asset Management’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242K	Buy	+4,252	New	+$203K	0.04%	167
2025 Q2	–	Sell	-7,487	Closed	-$238K	–	143
2025 Q1	$238K	Buy	7,487 +860	+13%	+$32.6K	0.06%	127
2024 Q4	$257K	Sell	6,627 -1,026	-13%	-$43.1K	0.07%	120
2024 Q3	$344K	Buy	7,653 +998	+15%	+$44.6K	0.09%	116
2024 Q2	$278K	Sell	6,655 -142	-2%	-$5.93K	0.08%	122
2024 Q1	$309K	Sell	6,797 -2,678	-28%	-$122K	0.07%	124
2023 Q4	$438K	Sell	9,475 -20,851	-69%	-$850K	0.12%	101
2023 Q3	$1.11M	Buy	30,326 +7,247	+31%	+$330K	0.34%	72
2023 Q2	$1.12M	Buy	23,079 +6,985	+43%	+$349K	0.42%	69
2023 Q1	$793K	Buy	16,094 +2,420	+18%	+$125K	0.35%	76
2022 Q4	$692K	Sell	13,674 -216	-2%	-$11.1K	0.35%	74
2022 Q3	$697K	Buy	13,890 +1,189	+9%	+$67.1K	0.43%	67
2022 Q2	$621K	Buy	12,701 +2,560	+25%	+$130K	0.38%	72
2022 Q1	$610K	Buy	+10,141	New	+$640K	0.33%	67

Other funds holding GNOM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

CFD

Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return

Manhattan West Asset Management's GNOM Position: Q2 2026 in Review

Manhattan West Asset Management opened a new position in Global X Genomics & Biotechnology ETF (GNOM) in Q2 2026: 4,252 shares worth $242K. The stake represents 0.04% of the portfolio and ranks #167 among its holdings. This is a return to the name: Manhattan West Asset Management previously reported a position in GNOM as recently as Q1 2025.

Manhattan West Asset Management first reported a position in GNOM in Q1 2022 and has held it in 14 quarters since. The position peaked at $1.12M in Q2 2023. 48 funds tracked by Wall St. Rank hold GNOM as of Q2 2026.

Manhattan West Asset Management held 4,252 shares of Global X Genomics & Biotechnology ETF worth $242K as of Q2 2026.
Global X Genomics & Biotechnology ETF was a new Manhattan West Asset Management position in Q2 2026.
Global X Genomics & Biotechnology ETF made up 0.04% of Manhattan West Asset Management's portfolio in Q2 2026, its #167 holding.
Manhattan West Asset Management first reported a position in Global X Genomics & Biotechnology ETF in Q1 2022 and has held it in 14 quarters since.
Manhattan West Asset Management's Global X Genomics & Biotechnology ETF position peaked at $1.12M in Q2 2023.
48 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q2 2026.

Based on Manhattan West Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.